Primary prophylaxis with G-CSF, used as daily filgrastim or once-per-cycle pegfilgrastim, reduces the severity and duration of chemotherapy-induced neutropenia and the consequent risk of FN, and plays an increasingly broad role in supporting the delivery of myelosuppressive chemotherapy [6–10]. The gene discussed is CSF3; the disease is neutropenia.